Jennifer D Richardson

US Patent:

6355430, Mar 12, 2002

Filed:

Dec 22, 1999

Appl. No.:

09/470614

Inventors:

Andrew W. Shyjan - San Carlos CA
Jennifer Richardson - Boston MA
John Vassiliadis - Marlborough MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 168

US Classification:

435 6, 536 2431, 536 2433, 536 235, 530350

Abstract:

The invention concerns the use of KIAA0101 nucleic acids and polypeptides in prostate cancer diagnostic and drug screening methods.

US Patent:

7572444, Aug 11, 2009

Filed:

Dec 16, 2005

Appl. No.:

11/303608

Inventors:

Ian Foltz - Burnaby, CA
Chadwick King - North Vancouver, CA
Peter Koon Bong Ling - Vancouver, CA
Jaspal Singh Kang - Surrey, CA
Kathy Manchulenko - Port Coquitlam, CA
Francine Chen - San Francisco CA, US
Caroline Darne Scatena - Alameda CA, US
Bruce A. Keyt - Hillsborough CA, US
Edwin Madison - San Francisco CA, US
Wayne R. Godfrey - Bainbridge Island WA, US
Stanislaw K. Morkowski - Lake Forest Park WA, US
Jennifer H. Richardson - Fremont CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Dendreon Corporation - Seattle WA

International Classification:

A61K 39/395
A61K 51/00
C07H 21/04
C12N 5/06
C12P 21/06

US Classification:

4241331, 424 149, 4241551, 4353201, 435338, 435 691, 536 2353

Abstract:

Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.

US Patent:

20210145978, May 20, 2021

Filed:

Nov 25, 2020

Appl. No.:

17/105402

Inventors:

- North Chicago IL, US
Jennifer Hope Richardson - Fremont CA, US
Laura Patterson Serwer - South San Francisco CA, US
Jonathan Alexander Terret - Lexington MA, US
Tracy Henriques - Evanston IL, US
Sherry L. Ralston - Lake Forest IL, US
Marvin Robert Leanna - Grayslake IL, US
Ilari Badagnani - Evanston IL, US
Sahana Bose - Marlborough MA, US

International Classification:

A61K 47/68
A61P 35/00
C07K 16/28

Abstract:

The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

US Patent:

20210047406, Feb 18, 2021

Filed:

Apr 24, 2020

Appl. No.:

16/858480

Inventors:

- South San Francisco CA, US
Sherry Lynn LA PORTE - San Francisco CA, US
Jason Gary SAGERT - San Mateo CA, US
Daniel Robert HOSTETTER - Palo Alto CA, US
Olivia Jennifer RAZO - Newark CA, US
Clayton William WHITE - San Francisco CA, US
Jennifer Hope RICHARDSON - Fremont CA, US

International Classification:

C07K 16/28
A61K 39/395
C07K 16/30
A61K 47/68

Abstract:

The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

US Patent:

20190111150, Apr 18, 2019

Filed:

Oct 12, 2018

Appl. No.:

16/159559

Inventors:

- North Chicago IL, US
Jennifer Hope RICHARDSON - Fremont CA, US
Laura Patterson SERWER - South San Francisco CA, US
Jonathan Alexander TERRETT - Lexington MA, US
Tracy HENRIQUES - Evanston IL, US
Sherry L. RALSTON - Lake Forest IL, US
Marvin Robert LEANNA - Grayslake IL, US
Ilaria BADAGNANI - Evanston IL, US
Sahana BOSE - Marlborough MA, US

International Classification:

A61K 47/68
A61P 35/00
C07K 16/28

Abstract:

The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

US Patent:

20160194399, Jul 7, 2016

Filed:

Jul 24, 2015

Appl. No.:

14/808711

Inventors:

- South San Francisco CA, US
Sherry Lynn La Porte - San Francisco CA, US
Jason Gary Sagert - San Mateo CA, US
Daniel Robert Hostetter - Palo Alto CA, US
Olivia Jennifer Razo - Newark CA, US
Clayton William White - San Francisco CA, US
Jennifer Hope Richardson - Fremont CA, US

International Classification:

C07K 16/28
A61K 47/48

Abstract:

The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.